Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ARDX
- Price
- 4.93
- Stock movement down
- -0.21 (-4.09%)
- Company name
- Ardelyx Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Markedsværdi
- 1.17B
- Ent værdi
- 1.33B
- Pris/omsætning
- 4.64
- Pris/bog
- 7.38
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -40.57%
- Efterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- -28.61%
- 1 års afkast
- -33.56%
- 3 års afkast
- 64.38%
- 5 års afkast
- -3.72%
- 10 års afkast
- -10.62%
Senest opdateret: 2025-03-28
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UDBYTTE
ARDX betaler ikke udbytte
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | 4.64 |
| Pris til egenkapital | 7.38 |
| EV i forhold til salg | 5.28 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 236.85M |
| EPS (TTM) | -0.31 |
| FCF pr. aktie (TTM) | -0.27 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 251.85M |
| Bruttofortjeneste (TTM) | 213.48M |
| Driftsindkomst (TTM) | -64.06M |
| Nettoindkomst (TTM) | -72.58M |
| EPS (TTM) | -0.31 |
| EPS (1 år frem) | -0.17 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | 84.76% |
| Driftsmargin (TTM) | -25.44% |
| Fortjenstmargin (TTM) | -28.82% |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 47.43M |
| Nettotilgodehavender | 53.20M |
| Omsætningsaktiver i alt | 284.10M |
| Goodwill | 0.00 |
| Immaterielle aktiver | 0.00 |
| Ejendomme, anlæg og udstyr | 4.65M |
| Sum aktiver | 367.86M |
| Kreditor | 15.82M |
| Kortfristet/nuværende langsigtet gæld | 104.49M |
| Summen af kortfristede forpligtelser | 70.50M |
| Sum gæld | 209.57M |
| Aktionærernes egenkapital | 158.30M |
| Materielle nettoaktiver | 0.00 |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | -63.34M |
| Investeringsudgifter (TTM) | 461.00K |
| Fri pengestrøm (TTM) | -63.80M |
| Udbetalt udbytte (TTM) | 25.89M |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | -45.85% |
| Afkast af aktiver | -19.73% |
| Afkast af investeret kapital | -27.48% |
| Kontant afkast af investeret kapital | -24.15% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 5.14 |
| Daglig høj | 5.14 |
| Daglig lav | 4.91 |
| Daglig volumen | 3.51M |
| Højeste gennem alle tider | 32.89 |
| 1 års analytiker estimat | 10.78 |
| Beta | 0.91 |
| EPS (TTM) | -0.31 |
| Udbytte pr. aktie | - |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | 30 Apr 2025 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| ARDX | S&P500 | |
| Nuværende prisfald fra top notering | -85.01% | -9.34% |
| Højeste prisfald | -98.45% | -56.47% |
| Højeste efterår dato | 14 Jun 2022 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -76.74% | -11.07% |
| Gennemsnitlig tid til nyt højdepunkt | 181 days | 12 days |
| Maks. tid til nyt højdepunkt | 2595 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
1.17B
Markedsværdi kategori
Small-cap
Beskrivelse
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Personale
267
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Michael G. Raab
Land
USA
By
Fremont
Aktietype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
iO Charts is a Seeking Alpha partner
Ardelyx, Inc. (NASDAQ:ARDX) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ETCompany ParticipantsCaitlin Lowie - Vice President of Corporate...
1. november 2024
iO Charts is a Seeking Alpha partner
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Seeking AlphaPressemeddelelser
Ardelyx's tenapanor targets IBS-C and hyperphosphatemia in CKD patients, showing strong revenue growth. Read why I downgrade ARDX stock from buy to hold.
25. september 2024
Ardelyx, Inc. (NASDAQ:ARDX) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ETCompany ParticipantsCaitlin Lowie - Vice President of Corporate...
2. august 2024
iO Charts is a Seeking Alpha partnerNæste side